Skip to main content

Acquired Immune Deficiency Syndrome

2
Pipeline Programs
5
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 3 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
Lopinavir 400 mg/ritonavir 100 mgPhase 41 trial
Active Trials
NCT00775606Terminated15Est. Jan 2011
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
first line ARVPhase 41 trial
Active Trials
NCT00872417Unknown750Est. Dec 2010
MSD
MSDIreland - Ballydine
1 program
RaltegravirN/ASmall Molecule1 trial
Active Trials
NCT00814879Completed60Est. Nov 2013
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
RaltegravirN/ASmall Molecule
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
1 program
Lopinavir 400 mg/ritonavir 100 mgPHASE_4

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
UNION therapeuticsfirst line ARV
Kite PharmaLopinavir 400 mg/ritonavir 100 mg
MSDRaltegravir

Clinical Trials (3)

Total enrollment: 825 patients across 3 trials

Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients

Start: Mar 2009Est. completion: Dec 2010750 patients
Phase 4Unknown
NCT00775606Kite PharmaLopinavir 400 mg/ritonavir 100 mg

Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

Start: Oct 2008Est. completion: Jan 201115 patients
Phase 4Terminated
NCT00814879MSDRaltegravir

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

Start: May 2009Est. completion: Nov 201360 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.